Most patients with HIV taking the investigational combination of islatravir (ISL; Merck) plus lenacapavir (LEN; Sunlenca, Gilead) maintained a high rate (94.2%) of viral suppression at 24 weeks, according to Amy Colson, MD, PhD, who presented the data at CROI 2024, held in Denver (abstract 208).
Only one participant in the phase 2 clinical study had a viral load of more than 50 copies/mL at week 24, but the participant later suppressed on ISL+LEN at week 30, according to